Dr Thomas observed that "licences were often given with conditions which demonstrated the CSM spotted deficiencies and assured they were rectified before the product was released on the market."
Linked evidence
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Duncan P Thomas